Brokerages expect Prestige Consumer Healthcare Inc. (NYSE:PBH) to post earnings per share of $0.99 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Prestige Consumer Healthcare’s earnings, with estimates ranging from $0.97 to $0.99. Prestige Consumer Healthcare reported earnings of $0.78 per share during the same quarter last year, which indicates a positive year over year growth rate of 26.9%. The company is scheduled to issue its next earnings results on Thursday, November 4th.
On average, analysts expect that Prestige Consumer Healthcare will report full year earnings of $3.98 per share for the current financial year, with EPS estimates ranging from $3.95 to $4.00. For the next year, analysts forecast that the business will post earnings of $4.25 per share, with EPS estimates ranging from $4.20 to $4.30. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Prestige Consumer Healthcare.
Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, August 5th. The company reported $1.14 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.87 by $0.27. The business had revenue of $269.10 million for the quarter, compared to the consensus estimate of $232.41 million. Prestige Consumer Healthcare had a return on equity of 13.25% and a net margin of 18.18%. The company’s revenue was up 17.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 EPS.
Several large investors have recently bought and sold shares of PBH. Janney Montgomery Scott LLC grew its stake in shares of Prestige Consumer Healthcare by 83.4% in the first quarter. Janney Montgomery Scott LLC now owns 17,569 shares of the company’s stock worth $774,000 after acquiring an additional 7,988 shares in the last quarter. Great Lakes Advisors LLC acquired a new position in shares of Prestige Consumer Healthcare during the first quarter worth $3,392,000. Victory Capital Management Inc. grew its stake in shares of Prestige Consumer Healthcare by 9.2% during the first quarter. Victory Capital Management Inc. now owns 44,044 shares of the company’s stock worth $1,941,000 after purchasing an additional 3,701 shares in the last quarter. Dean Investment Associates LLC grew its stake in shares of Prestige Consumer Healthcare by 33.6% during the first quarter. Dean Investment Associates LLC now owns 57,091 shares of the company’s stock worth $2,517,000 after purchasing an additional 14,350 shares in the last quarter. Finally, Seizert Capital Partners LLC grew its stake in shares of Prestige Consumer Healthcare by 46.5% during the first quarter. Seizert Capital Partners LLC now owns 71,016 shares of the company’s stock worth $3,130,000 after purchasing an additional 22,538 shares in the last quarter.
Shares of NYSE PBH traded down $0.30 during trading hours on Friday, hitting $53.48. 3,903 shares of the company traded hands, compared to its average volume of 363,704. The company’s 50 day moving average price is $55.28 and its 200 day moving average price is $50.18. The stock has a market capitalization of $2.68 billion, a price-to-earnings ratio of 15.24, a price-to-earnings-growth ratio of 3.36 and a beta of 0.69. The company has a current ratio of 3.27, a quick ratio of 2.42 and a debt-to-equity ratio of 1.10. Prestige Consumer Healthcare has a 12 month low of $32.19 and a 12 month high of $60.57.
About Prestige Consumer Healthcare
Prestige Consumer Healthcare, Inc engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody’s, Beano, Boudreaux’s Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden’s, Monistat, Nix, Pedia-Lax, and Summer’s Eve.
Recommended Story: Trade War
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.